Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BTG buys Protherics

Executive Summary

BTG PLC has agreed to acquire Protherics PLC (critical care and cancer therapeutics) for about £218mm ($419mm) in stock. BTG will issue 0.291 share (worth £0.60) for each of Protherics' 342mm shares and additional shares resulting from conversion rights and the exercise of issued options. This is a 98% premium compared to Protherics' stock price back in August when the company initially announced it was entertaining acquisition offers.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies